4 479

Cited 20 times in

Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition

DC Field Value Language
dc.contributor.author이윤한-
dc.date.accessioned2015-01-06T16:29:28Z-
dc.date.available2015-01-06T16:29:28Z-
dc.date.issued2014-
dc.identifier.issn0006-291X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/98204-
dc.description.abstractThe PI3K/Akt/mTOR axis in lung cancer is frequently activated and implicated in tumorigenesis. Specific targeting of this pathway is therefore an attractive therapeutic approach for lung cancer. However, non-small cell lung cancer cells are resistant to BEZ235, a dual inhibitor of PI3K and mTOR. Interestingly, blockage of Stat3 with a selective inhibitor, S3I-201, or siRNA dramatically sensitized the BEZ235-induced cell death, as evident from increased PARP cleavage. Furthermore, inhibition of Stat3 led to enhancement of cell death induced by LY294002, a PI3K inhibitor. Treatment of cells with a combination of BEZ235 and S3I-201 significantly induced the proapoptotic transcription factor, CHOP, and its targets, Bim and DR4. Knockdown of CHOP or Bim suppressed cell death stimulated by the combination treatment, implicating the involvement of these BEZ235/S3I-201-induced factors in pronounced cell death. Moreover, the BEZ235/S3I-201 combination enhanced TRAIL-induced cell death. Our results collectively suggest that blockage of Stat3 presents an effective strategy to overcome resistance to PI3K/Akt/mTOR inhibition.-
dc.description.statementOfResponsibilityopen-
dc.format.extent502~508-
dc.relation.isPartOfBIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAminosalicylic Acids/pharmacology-
dc.subject.MESHAntineoplastic Agents/pharmacology-
dc.subject.MESHBenzenesulfonates/pharmacology*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/genetics-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/metabolism-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/pathology-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHDrug Resistance, Neoplasm/drug effects-
dc.subject.MESHHumans-
dc.subject.MESHImidazoles/pharmacology*-
dc.subject.MESHLung/drug effects-
dc.subject.MESHLung/metabolism-
dc.subject.MESHLung/pathology-
dc.subject.MESHLung Neoplasms/drug therapy*-
dc.subject.MESHLung Neoplasms/genetics-
dc.subject.MESHLung Neoplasms/metabolism-
dc.subject.MESHLung Neoplasms/pathology-
dc.subject.MESHPhosphatidylinositol 3-Kinases/antagonists & inhibitors*-
dc.subject.MESHPhosphatidylinositol 3-Kinases/metabolism-
dc.subject.MESHProtein Kinase Inhibitors/pharmacology*-
dc.subject.MESHQuinolines/pharmacology*-
dc.subject.MESHRNA Interference-
dc.subject.MESHRNA, Small Interfering/genetics-
dc.subject.MESHSTAT3 Transcription Factor/antagonists & inhibitors*-
dc.subject.MESHSTAT3 Transcription Factor/genetics-
dc.subject.MESHSignal Transduction/drug effects-
dc.subject.MESHTOR Serine-Threonine Kinases/antagonists & inhibitors*-
dc.subject.MESHTOR Serine-Threonine Kinases/metabolism-
dc.titleBlockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학)-
dc.contributor.googleauthorHyeon-Ok Jin-
dc.contributor.googleauthorYun-Han Lee-
dc.contributor.googleauthorJin-Ah Park-
dc.contributor.googleauthorJin-Hee Kim-
dc.contributor.googleauthorSung-Eun Hong-
dc.contributor.googleauthorHyun-Ah Kim-
dc.contributor.googleauthorEun-Kyu Kim-
dc.contributor.googleauthorWoo Chul Noh-
dc.contributor.googleauthorByung-Hak Kim-
dc.contributor.googleauthorSang-Kyu Ye-
dc.contributor.googleauthorYoon Hwan Chang-
dc.contributor.googleauthorSeok-Il Hong-
dc.contributor.googleauthorYoung-Joon Hong-
dc.contributor.googleauthorIn-Chul Park-
dc.contributor.googleauthorJin Kyung Lee-
dc.identifier.doi10.1016/j.bbrc.2014.01.086-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03029-
dc.relation.journalcodeJ00281-
dc.identifier.eissn1090-2104-
dc.identifier.pmid24472538-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0006291X14001107-
dc.subject.keywordAkt-
dc.subject.keywordBim-
dc.subject.keywordCHOP-
dc.subject.keywordPI3K-
dc.subject.keywordStat3-
dc.subject.keywordmTOR-
dc.contributor.alternativeNameLee, Yun Han-
dc.contributor.affiliatedAuthorLee, Yun Han-
dc.rights.accessRightsfree-
dc.citation.volume444-
dc.citation.number4-
dc.citation.startPage502-
dc.citation.endPage508-
dc.identifier.bibliographicCitationBIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol.444(4) : 502-508, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.